Veracyte Inc
VCYT
NASDAQ
Biotechnology
$41.25
USD
-1.35 (-3.17%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.35B
Volume 1.7M
Revenue
$561.90M
TTM
+17.3%
YoY
Gross Margin
72%
TTM
+5.1%
YoY
Net Income
$114.48M
TTM
+334.7%
YoY
Operating Cash Flow
$178.38M
TTM
+90.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 130.2 | 131.9 | 140.6 | 139.1 | 150.3 |
YoY Growth | +13.8% | +13.8% | +18.5% | +21.5% | +15.5% |
Cost of Revenue | 40.4 | 40.6 | 38.7 | 37.9 | 41.8 |
Gross Profit | 89.8 | 91.3 | 102.0 | 101.2 | 108.5 |
Selling, General & Administrative | 57.6 | 51.7 | 43.3 | 50.8 | 55.7 |
Other Operating Expenses | 20.5 | 0.0 | 2.5 | 0.0 | 0.0 |
Total Operating Expenses | 95.0 | 68.3 | 64.8 | 78.5 | 85.6 |
Operating Income | -5.3 | 22.9 | 37.2 | 22.6 | 23.0 |
EBITDA | 20.7 | 28.2 | 42.5 | 28.1 | 27.8 |
Other Income / Expense | 6.5 | -4.1 | 3.4 | 7.3 | 3.5 |
Total Other Income / Expense | 6.5 | -4.1 | 3.4 | 7.3 | 3.5 |
Income Before Income Taxes | 1.3 | 18.9 | 40.6 | 30.0 | 26.5 |
Income Taxes | 2.2 | -0.2 | -0.5 | 1.3 | 1.0 |
Net Income | -1.0 | 19.1 | 41.1 | 28.7 | 25.5 |
Consolidated Net Income / Loss | -1.0 | 19.1 | 41.1 | 28.7 | 25.5 |
Net Income Attributable to Common Shareholders | -1.0 | 19.1 | 41.1 | 28.7 | 25.5 |
Basic EPS | -$0.01 | $0.24 | $0.52 | $0.36 | $0.32 |
Diluted EPS | -$0.01 | $0.24 | $0.49 | $0.35 | $0.31 |
Basic Shares Outstanding | 78.4M | 78.7M | 79.2M | 79.5M | 80.0M |
Diluted Shares Outstanding | 78.4M | 79.7M | 84.2M | 81.3M | 82.1M |